These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 2760017)

  • 21. Defective VLDL metabolism and severe atherosclerosis in mice expressing human apolipoprotein E isoforms but lacking the LDL receptor.
    Knouff C; Briand O; Lestavel S; Clavey V; Altenburg M; Maeda N
    Biochim Biophys Acta; 2004 Aug; 1684(1-3):8-17. PubMed ID: 15450205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stable incorporation of a lipophilic daunorubicin prodrug into apolipoprotein E-exposing liposomes induces uptake of prodrug via low-density lipoprotein receptor in vivo.
    Versluis AJ; Rump ET; Rensen PC; van Berkel TJ; Bijsterbosch MK
    J Pharmacol Exp Ther; 1999 Apr; 289(1):1-7. PubMed ID: 10086980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Behavior of human apolipoprotein E in aqueous solutions and at interfaces.
    Yokoyama S; Kawai Y; Tajima S; Yamamoto A
    J Biol Chem; 1985 Dec; 260(30):16375-82. PubMed ID: 4066713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of apoE on triglyceride emulsion interaction with hepatocyte and hepatoma G2 cells.
    Oswald B; Quarfordt S
    J Lipid Res; 1987 Jul; 28(7):798-809. PubMed ID: 3625037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-density lipoprotein receptor-mediated delivery of a lipophilic daunorubicin derivative to B16 tumours in mice using apolipoprotein E-enriched liposomes.
    Versluis AJ; Rensen PC; Rump ET; Van Berkel TJ; Bijsterbosch MK
    Br J Cancer; 1998 Dec; 78(12):1607-14. PubMed ID: 9862571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Model of biologically active apolipoprotein E bound to dipalmitoylphosphatidylcholine.
    Peters-Libeu CA; Newhouse Y; Hatters DM; Weisgraber KH
    J Biol Chem; 2006 Jan; 281(2):1073-9. PubMed ID: 16278220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ligand size as a determinant for catabolism by the low density lipoprotein (LDL) receptor pathway. A lattice model for LDL binding.
    Chappell DA; Fry GL; Waknitz MA; Berns JJ
    J Biol Chem; 1991 Oct; 266(29):19296-302. PubMed ID: 1918046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the LDL-receptor binding of VLDL and LDL from apoE4 and apoE3 homozygotes.
    Mamotte CD; Sturm M; Foo JI; van Bockxmeer FM; Taylor RR
    Am J Physiol; 1999 Mar; 276(3):E553-7. PubMed ID: 10070023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A continuum receptor model of hepatic lipoprotein metabolism.
    Tindall MJ; Wattis JA; O'Malley BJ; Pickersgill L; Jackson KG
    J Theor Biol; 2009 Apr; 257(3):371-84. PubMed ID: 19109979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rate and equilibrium constants for binding of apo-E HDLc (a cholesterol-induced lipoprotein) and low density lipoproteins to human fibroblasts: evidence for multiple receptor binding of apo-E HDLc.
    Pitas RE; Innerarity TL; Arnold KS; Mahley RW
    Proc Natl Acad Sci U S A; 1979 May; 76(5):2311-5. PubMed ID: 221921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in receptor binding of LDL subfractions.
    Campos H; Arnold KS; Balestra ME; Innerarity TL; Krauss RM
    Arterioscler Thromb Vasc Biol; 1996 Jun; 16(6):794-801. PubMed ID: 8640407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Properties of human plasma lipid transfer protein in aqueous solution and at interfaces.
    Ohnishi T; Hicks LD; Oikawa K; Kay CM; Yokoyama S
    Biochemistry; 1994 May; 33(20):6093-9. PubMed ID: 8193123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A synthetic low density lipoprotein particle capable of supporting U937 proliferation in vitro.
    Baillie G; Owens MD; Halbert GW
    J Lipid Res; 2002 Jan; 43(1):69-73. PubMed ID: 11792724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The HepG2 extracellular matrix contains separate heparinase- and lipid-releasable pools of ApoE. Implications for hepatic lipoprotein metabolism.
    Burgess JW; Gould DR; Marcel YL
    J Biol Chem; 1998 Mar; 273(10):5645-54. PubMed ID: 9488694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preparation of apoE-free rat low density lipoprotein for catabolic studies.
    Schlag B; Winkler L; Plonné D; Dürer U; Dargel R
    J Lipid Res; 1987 Dec; 28(12):1521-4. PubMed ID: 3430074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthetic oligonucleotide does not bind to lipid emulsion resembling low-density lipoprotein.
    Bydlowski SP; Vinagre CG; Bravo LM; Debes AA; Maranhão RC
    Ann N Y Acad Sci; 1995 Nov; 772():252-4. PubMed ID: 8546400
    [No Abstract]   [Full Text] [Related]  

  • 37. Receptor-independent low-density lipoprotein catabolism.
    Shepherd J; Packard CJ
    Methods Enzymol; 1986; 129():566-90. PubMed ID: 3523158
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phospholipid monolayers at the triolein-saline interface: production of microemulsion particles and conversion of monolayers to bilayers.
    Handa T; Saito H; Miyajima K
    Biochemistry; 1990 Mar; 29(11):2884-90. PubMed ID: 2346751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis of a lipophilic daunorubicin derivative and its incorporation into lipidic carriers developed for LDL receptor-mediated tumor therapy.
    Versluis AJ; Rump ET; Rensen PC; Van Berkel TJ; Bijsterbosch MK
    Pharm Res; 1998 Apr; 15(4):531-7. PubMed ID: 9587947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low density lipoprotein for cytotoxic drug targeting: improved activity of elliptinium derivative against B16 melanoma in mice.
    Samadi-Baboli M; Favre G; Canal P; Soula G
    Br J Cancer; 1993 Aug; 68(2):319-26. PubMed ID: 8347487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.